ACTU — Actuate Therapeutics Balance Sheet
0.000.00%
- $135.47m
- $129.38m
Annual balance sheet for Actuate Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|
| Period Length: | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | 10-K |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Cash and Equivalents | |||
| Cash and Short Term Investments | 20.4 | 2.96 | 8.64 |
| Prepaid Expenses | |||
| Total Current Assets | 20.5 | 3 | 9.21 |
| Other Long Term Assets | |||
| Total Assets | 20.5 | 3 | 9.32 |
| Accounts Payable | |||
| Accrued Expenses | |||
| Notes Payable / Short Term Debt | |||
| Total Current Liabilities | 4.34 | 6.92 | 8.8 |
| Long Term Debt | |||
| Total Long Term Debt | |||
| Total Debt | |||
| Total Other Liabilities | |||
| Total Liabilities | 5.65 | 8.44 | 9.21 |
| Redeemable Preferred Stock | |||
| Non Redeemable Preferred Stock | |||
| Common Stock | |||
| Additional Paid In Capital | |||
| Retained Earnings (Accumulated Deficit) | |||
| Total Equity | 14.8 | -5.45 | 0.104 |
| Total Liabilities & Shareholders' Equity | 20.5 | 3 | 9.32 |
| Total Common Shares Outstanding | |||
| Total Preferred Shares Outstanding |